SHAOXING, China, May 8, 2026 /PRNewswire/ -- Recently, the novel oral BET inhibitor NHWD-870Â HCI, independently developed by Zhejiang Wenda Pharmaceutical Technology Co., Ltd., officially received Breakthrough Therapy Designation from the China National Medical Products Administration (NMPA) for the proposed indication of advanced thoracic midline (NUT) carcinoma in patients who have failed prior chemotherapy. This milestone progress brings new targeted therapy hope to NUT carcinoma patients, a disease with extremely high malignancy and a very poor prognosis.
kAm}&% 42C4:?@>2 :D 2 C2C6[ A@@C=J 5:776C6?E:2E65 42C4:?@>2 492C24E6C:K65 3J }&%|` 86?6 C62CC2?86>6?E] %96 5:D62D6 AC@8C6DD6D C2A:5=J[ H:E9 2 >65:2? DFCG:G2= @7 @?=J 2AAC@I:>2E6=J e]d >@?E9D] xE 4@>>@?=J @44FCD :? E96 =F?8D[ 9625[ 2?5 ?64< C68:@?D[ 2?5 E96 >65:2? 286 @7 @?D6E :D @?=J ab]e J62CD] sF6 E@ E96 =24< @7 DA64:7:4:EJ :? 4=:?:42= >2?:76DE2E:@?D 2?5 :?DF77:4:6?E 2H2C6?6DD 2>@?8 E96 AF3=:4[ E96 C2E6D @7 >:D5:28?@D:D 2?5 >:DD65 5:28?@D:D 2C6 6IEC6>6=J 9:89[ 2?5 >@DE A2E:6?ED 2C6 2=C625J 2E 2? 25G2?465 DE286 2E E96 E:>6 @7 5:28?@D:D] rFCC6?E=J[ ?@ 67764E:G6 E2C86E65 5CF8 7@C }&% 42C4:?@>2 92D 366? 2AAC@G65 8=@32==J[ 2?5 E96 EC62E>6?E =2?5D42A6 :D 6IEC6>6=J 5:C6]k^Am
kAm%96 8C2?E:?8 @7 qC62<E9C@F89 %96C2AJ s6D:8?2E:@? E@ }w(s\gf_ wrx :D AC:>2C:=J 32D65 @? E96 D:8?:7:42?E 677:424J 2?5 DFCG:G2= 36?67:ED 56>@?DEC2E65 :? :ED !92D6 xx 4=:?:42= DEF5J] pD @7 s646>36C af[ a_ad[ 2 E@E2= @7 c_ 6G2=F23=6 DF3;64ED H:E9 25G2?465 }&% 42C4:?@>2 H6C6 6?C@==65 :? E96 DEF5J] %96 52E2 D9@H65 E92E E96 5CF8 6I9:3:E65 A@D:E:G6 2?E:\EF>@C 24E:G:EJ 24C@DD 5:776C6?E =6D:@? D:E6Di E96 @3;64E:G6 C6DA@?D6 C2E6 W~##X :? a_ A2E:6?ED H:E9 25G2?465 E9@C24:4 }&% 42C4:?@>2 C624965 2D 9:89 2D cd]__Tj E96 >65:2? @G6C2== DFCG:G2= W>~$X 7@C 25G2?465 E9@C24:4 }&% 42C4:?@>2 A2E:6?ED 2?5 7@C 2== DF3;64ED 3@E9 C624965 h]bb >@?E9D[ C6AC6D6?E:?8 2 D:8?:7:42?E 6IE6?D:@? 4@>A2C65 H:E9 DE2?52C5 496>@E96C2AJ C68:>6?D] rFCC6?E=J[ D@>6 A2E:6?ED 2C6 DE:== C646:G:?8 @?8@:?8 EC62E>6?E 2?5 4=@D6 7@==@H\FA] x? 255:E:@?[ AC6=:>:?2CJ D276EJ 52E2 D9@H65 E92E E96 5CF8 H2D 86?6C2==J H6== E@=6C2E65 2?5 96=5 9:89 A@E6?E:2= 7@C 4=:?:42= 2AA=:42E:@?]k^Am
kAm%9:D qC62<E9C@F89 %96C2AJ s6D:8?2E:@? :D @7 8C62E D:8?:7:42?46 7@C }&% 42C4:?@>2 A2E:6?ED 2?5 C6AC6D6?ED 2 =62A7C@8 25G2?46 :? E96 7:6=5] u@C A2E:6?ED[ :E >62?D E92E E96 C68F=2E@CJ C6G:6H AC@46DD 7@C }w(s\gf_ wrx H:== 36 2446=6C2E65 2?5 E96 5CF8 H:== C6249 E96 >2C<6E D@@?6C[ 6?23=:?8 A2E:6?ED H:E9 25G2?465 }&% 42C4:?@>2 E@ C646:G6 E2C86E65 E96C2AJ 62C=:6C 2?5 6D42A6 E96 5:=6>>2 @7 92G:?8 ?@ 67764E:G6 5CF8[ E96C63J D:8?:7:42?E=J AC@=@?8:?8 DFCG:G2= 2?5 :>AC@G:?8 BF2=:EJ @7 =:76] ~? E96 4=:?:42= =6G6=[ E96 56G6=@A>6?E 2?5 56D:8?2E:@? @7 E9:D 5CF8 7:== E96 82A :? E2C86E65 EC62E>6?E 7@C }&% 42C4:?@>2 2?5 AC@G:56 4=:?:4:2?D H:E9 2 4@>A=6E6=J ?6H EC62E>6?E @AE:@?] %9:D ?@E @?=J 5C:G6D E96 EC2?D7@C>2E:@? @7 }&% 42C4:?@>2 EC62E>6?E 7C@> QDJ>AE@>2E:4 EC62E>6?EQ E@ QAC64:D:@? E2C86E65 E96C2AJQ 3FE 2=D@ AC@G:56D G2=F23=6 4=:?:42= 6IA6C:6?46 7@C E96 7FEFC6 56G6=@A>6?E @7 D:>:=2C 5CF8D]k^Am
kAmkDA2? :5lQDA2?w89=Ech_3Qm|C] }6?89F: (2?8[k^DA2?m u@F?56C @7Â (6?52 !92C>2[ DE2E65i Q(6 2C6 56=:89E65 E92E @FC AC@5F4E 92D C646:G65 qC62<E9C@F89 %96C2AJ s6D:8?2E:@?] %9:D AC@8C6DD 9:89=:89ED r9:?2VD 8C@H:?8 42A23:=:E:6D :? :??@G2E:G6 5CF8 56G6=@A>6?E 7@C C2C6 42?46CD] }w(s\gf_ ?@E @?=J 3C:?8D 9@A6 E@ }&% 42C4:?@>2 A2E:6?ED 3FE 2=D@ @776CD ?6H 2G6?F6D 7@C 6IA=@C:?8 EC62E>6?ED 7@C @E96C C2C6 >2=:8?2?4:6D]Qk^Am
kAm!C@76DD@C *x} |:?8K9F[ s:C64E@C @7 E96 |:5=:?6 W}&%X r2C4:?@>2 $A64:2=EJ 2E E96 p77:=:2E65 %9C66 v@C86D w@DA:E2= @7 r9@?8B:?8 &?:G6CD:EJ[ ?@E65[ Q}&% 42C4:?@>2 @?46 A=F?865 4@F?E=6DD A2E:6?ED 2?5 5@4E@CD :?E@ 56DA2:C] %96 qC62<E9C@F89 %96C2AJ s6D:8?2E:@? 7@C }w(s\gf_ :D 2? :>A@CE2?E 249:6G6>6?E :?E68C2E:?8 >65:42= C6D62C49 2?5 4=:?:42= AC24E:46] x? E96 7FEFC6[ H:E9 E96 2446=6C2E65 >2C<6E 6?ECJ @7 E9:D 5CF8[ E96 EC62E>6?E =2?5D42A6 @7 }&% 42C4:?@>2 :D 6IA64E65 E@ 36 4@>A=6E6=J EC2?D7@C>65[ :?;64E:?8 ?6H >@>6?EF> :?E@ E96 42FD6 @7 C2C6 5:D62D6 5:28?@D:D 2?5 EC62E>6?E :? @FC 4@F?ECJ]Qk^Am
kAmkDA2? :5lQDA2?w89=Ege5dQmkDEC@?8mp3@FE (6?52 !92C>2k^Am
kAmk^DEC@?8mu@F?565k^DA2?m :? a_`b 2?5 9625BF2CE6C65 :? $92@I:?8 r:EJ[ r9:?2] (6?52 !92C>2 :D 2 4@>A2?J 565:42E65 E@ A:@?66C:?8[ :??@G2E:G6[ 2?5 9:89\BF2=:EJ 5CF8 5:D4@G6CJ] %96 4@>A2?J 7@4FD6D :ED C6D62C49 :? E96 2C62D @7 @?4@=@8J[ :>>F?@=@8J[ 2?5 ?6FC@5686?6C2E:G6 5:D62D6D[ H:E9 >F=E:A=6 r9:?6D6 2?5 8=@32= A2E6?E 2AA=:42E:@?D 2?5 8C2?ED :? E96D6 7:6=5D] $6G6C2= @7 E96 4@>A2?JVD 5CF8 42?5:52E6D 2C6 4FCC6?E=J :? !92D6 x[ xx[ 2?5 xxx 4=:?:42= EC:2=D]k^Am
kAm%96 }w(s\gf_ AC@8C2>[ E2C86E:?8 E96 C2C6 }&% 42C4:?@>2[ 92D DF446DD7F==J 4@>A=6E65 !92D6 xx 4=:?:42= EC:2=D 2?5 9@=5D E96 A@E6?E:2= E@ 364@>6 2 Qu:CDE\:?\r=2DDQ @C2= D>2==\>@=64F=6 qt% :?9:3:E@C[ @776C:?8 A2E:6?ED E96 9@A6 @7 6IE6?565 DFCG:G2=] p55:E:@?2==J[ E96 r@>A2?JVD (s\gh_ %*za WywaX :?9:3:E@C—:?5:42E65 7@C >@56C2E6\E@\D6G6C6 A=2BF6 AD@C:2D:D—92D 6?E6C65 !92D6 xxx 4=:?:42= EC:2=D[ H9:=6 !92D6 xx EC:2=D 7@C E96 DJDE6>:4 =FAFD 6CJE96>2E@DFD W${tX :?5:42E:@? 2C6 2=D@ D6E E@ 4@>>6?46 D9@CE=J] (s\h`_[ 2 E96C2A6FE:4 42?5:52E6 E2C86E:?8 ?6FC@5686?6C2E:G6 5:D62D6D[ :D A@:D65 E@ 6?E6C !92D6 xx 4=:?:42= EC:2=D :? r9:?2[ H9:49 ;FDE 4@>A=6E65 A92D6 x 4=:?:42= EC:2= :? kDA2? :5lQDA2?w89=Ebb7cQmpFDEC2=:2[k^DA2?m :ED `__T 3=@@5\3C2:? 32CC:6C A6?6EC2E:@? 42A23:=:EJ A@D:E:@?D :E 2D 2 A@E6?E:2= Qq6DE\:?\r=2DDQ 5CF8 42?5:52E6] (6?52 !92C>2 3@2DED 2 C:49 2?5 :??@G2E:G6 A:A6=:?6 E2C86E:?8 ?F>6C@FD C67C24E@CJ 2?5 :?4FC23=6 5:D62D6D[ DEC:G:?8 E@ AC@G:56 A2E:6?ED H:E9 >@C6 67764E:G6[ D276[ 2?5 4@DE\67764E:G6 :??@G2E:G6 >65:4:?6D]k^Am
kAmkDA2? :5lQDA2?w89=E45bcQmk2 9C67lQ9EEADi^^HHH]H6?52A92C>2]4@>^Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQmkDA2? :5lQDA2?w89=E`_eeQmHHHk^DA2?m]H6?52A92C>2]4@>k^2mk^Am
kAmu@C k^DA2?mkDA2? :5lQDA2?w89=E3c6fQmqk^DA2?ms 2?5 x?G6DE@CDi k2 9C67lQ>2:=E@iqsoH6?52A92C>2]4@>Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQmqsoH6?52A92C>2]4@>k^2m k^Am
k5:G 4=2DDlQ!#}0x>365565pDD6E#676C6?46Q :5lQs:GpDD6E!=246w@=56C_Qmk^5:Gm
kA :5lQ!&#{Qmk:>8 E:E=6lQr:D:@?Q H:5E9lQ`aQ 96:89ElQ`aQ 2=ElQr:D:@?Q DC4lQ9EEADi^^6586]AC?6HDH:C6]4@>^4^:>8^72G:4@?]A?8nD?lr}dbfd`U2>AjD5la_ae\_d\_gQ ^m ':6H @C:8:?2= 4@?E6?E E@ 5@H?=@25 >F=E:>65:2ik2 :5lQ!#}&#{Q C6=lQ?@7@==@HQ 9C67lQ9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^49:?2\:??@G2E:G6\5CF8\?9H5\gf_\C646:G6D\3C62<E9C@F89\E96C2AJ\56D:8?2E:@?\3C:?8:?8\?6H\9@A6\@7\DFCG:G2=\E@\?FE\42C4:?@>2\A2E:6?ED\b_afeeh`h]9E>=Q E2C86ElQ03=2?<Qm9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^49:?2\:??@G2E:G6\5CF8\?9H5\gf_\C646:G6D\3C62<E9C@F89\E96C2AJ\56D:8?2E:@?\3C:?8:?8\?6H\9@A6\@7\DFCG:G2=\E@\?FE\42C4:?@>2\A2E:6?ED\b_afeeh`h]9E>=k^2mk^Am
kAm$~&#rt +96;:2?8 (6?52 !92C>246FE:42= %649?@=@8J r@][ {E5]k^Am
kAmk:>8 2=ElQQ DC4lQ9EEADi^^CE]AC?6HDH:C6]4@>^CE]8:7n}6HDxE6>x5lr}dbfd`U2>Aj%C2?D>:DD:@?0x5la_ae_d_ga_b_!#0}t($0&$!#00000r}dbfd`U2>Ajs2E6x5la_ae_d_gQ DEJ=6lQ3@C56Ci_AIj H:5E9i`AIj 96:89Ei`AIjQ ^mk^Am
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.